At a Glance
- Company: Cognito Therapeutics
- Location: Cambridge, Massachusetts
- Deal value: $105M oversubscribed Series C
- Focus area: Spectris non-invasive neurostimulation for Alzheimer’s
- Next steps: HOPE pivotal data; FDA submission, 2027 launch
What happened?
Cognito Therapeutics announced the close of its oversubscribed $105 million Series C financing on 5 March 2026, led by Morningside Ventures, IAG Capital Partners and Starbloom Capital. New investors including Apollo Health Ventures, Benvolio Group and New Vintage participated, bringing total funding to $233 million.
Why does it matter?
Alzheimer’s affects 50M+ globally with few disease-modifying options; Spectris uses 40Hz light/sound stimulation to drive gamma oscillations, slowing atrophy and preserving cognition per phase 2 OVERTURE data (76% less decline). Funds enable commercial scale-up in $15B+ US market.
Who’s behind it?
Cognito develops sensory neuromodulation; MIT spinout with ADDF support. CEO Christian Howell leads execution toward at-home prescription device.
How was it achieved?
Spectris headset delivers visual/auditory entrainment to connected brain networks; HOPE pivotal fully enrolled with topline data H2 2026. Feasibility studies showed cognitive/function benefits in mild-moderate AD.
What’s next?
Pivotal readout, FDA submission and 2027 US launch; expand to other neurodegeneration via WVU Rockefeller Institute. Funds support regulatory/commercial infrastructure.
What are people saying?
CEO Howell: “Pivotal moment… first at-home neuroprotective therapy.” Gerald Chan (Morningside): “Redefines neurodegenerative treatment.”